<DOC>
	<DOC>NCT01299857</DOC>
	<brief_summary>The purpose of this study is to study the midterm clinical evaluation, biological parameters and immune reconstitution after Rituximab treatment for Pemphigus.</brief_summary>
	<brief_title>Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Pemphigus</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>age&gt;18 consentment patient treated with Rituximab and included in clinical trial n°2002/020/HP NCT00213512 "Treatment of Patients Presenting Pemphigus With Anti CD20 (Mabthera)". age &lt; 18 no consentment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>pemphigus</keyword>
	<keyword>Mabthéra (R)</keyword>
	<keyword>B lymphocytes</keyword>
	<keyword>desmogleines</keyword>
</DOC>